Šīs tīmekļa vietnes satura kvalitātes uzlabošanai un pielāgošanai lietotāju vajadzībām tiek lietotas sīkdatnes - tai skaitā arī trešo pušu sīkdatnes. Turpinot lietot šo vietni Jūs piekrītat sīkdatņu lietošanai.
Mr. Sergejs Bataļins has been elected as a Member of the Board of JSC “Grindeks”
Emitents Grindeks, AS (5299006DWR32NKWM1O86)
Veids Būtiski notikumi
Valoda EN
Statuss Publicēts
Versija
Datums 2014-07-03 17:31:45
Versijas komentārs
Teksts

Riga, 3 July 2014

JSC ”Grindeks” informs that in compliance with the decision of Supervisory Council of JSC “Grindeks” Mr. Sergejs Bataļins has been elected as a Member of the Board of JSC “Grindeks”.

Mr. S. Bataļins was born in 1975. Graduated from Moscow Commercial University, where he studied International Economics. He is the Commercial Director for JSC ”Grindeks” since December 2013. Previously, he worked at ”BLRT Masinaehitus”, part of BLRT group as the Executive Director and has also held leading positions in companies, such as ”Baltrotors” Ltd., ”Nelss Logi” Ltd., ”Staburadzes konditoreja” Ltd., ”Euro Food” Ltd. and ”NP Foods” Ltd.

Mr. S. Bataļins doesn’t own shares of JSC ”Grindeks”.

The Chairman of the Board Mr. Juris Bundulis and the Member of the Board, Chief Finance and Administrative Officer Mr. Vadims Rabša continue their work in the Board of JSC ”Grindeks”.

About “Grindeks”

“Grindeks” is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” consists of four subsidiary companies in Latvia, Estonia and Russia, as well as representative offices in 13 countries.

“Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Currently “Grindeks” produces 25 active pharmaceutical ingredients.

Products of the company are exported to 59 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany, the Netherlands, Japan and the U.S.

To increase production capacity and develop infrastructure, since 2002 the company has accomplished many significant investment projects, investing 70.7 million euros over the years.

JSC “Grindeks” shares are listed on the Official List of “NASDAQ OMX Riga”. Major shareholders of JSC “Grindeks” are Kirovs Lipmans – 33.29%, “AB.LV Private Equity fund 2010” – 22.66%, Anna Lipmane – 16.69%, “Swedbank” AS Clients Account (nominee account) – 10.47%.

 

More information about the company – www.grindeks.lv/en/

Follow “Grindeks”:
Twitter.com/AS_Grindeks; Youtube.com/GrindeksLV 

 

Additional information:
Laila Kļaviņa
Head of the Communications Department JSC “Grindeks”
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
E-mail: laila.klavina@grindeks.lv

Pielikumi